Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.
L, R., R, A., A, A.M., S, Q., M, A., K, H., & AR, A. (2026). Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.. Wiadomosci lekarskie (Warsaw, Poland : 1960). https://doi.org/10.36740/WLek/216191
L R, R A, A AM, S Q, M A, K H, et al. Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2026; doi: 10.36740/WLek/216191
L R, R A, A AM, et al. Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.[J]. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2026. DOI: 10.36740/WLek/216191.
@article{l2026,
author = {Rhabneh L and Ababneh R and Al-Muhtaseb A and Qaddour S and Aloqaily M and Hazaimeh K and Alwardat AR},
title = {Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.},
journal = {Wiadomosci lekarskie (Warsaw, Poland : 1960)},
year = {2026},
doi = {10.36740/WLek/216191},
note = {PMID: 42359860},
}
TY - JOUR AU - Rhabneh L AU - Ababneh R AU - Al-Muhtaseb A AU - Qaddour S AU - Aloqaily M AU - Hazaimeh K AU - Alwardat AR TI - Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis. T2 - Wiadomosci lekarskie (Warsaw, Poland : 1960) PY - 2026 DO - 10.36740/WLek/216191 AN - PMID:42359860 ER -
OBJECTIVE: Aim: The primary endpoint was the incidence of major HRAEs. Secondary endpoints included LVAD thrombosis, stroke, major bleeding, non-central nervous system thromboembolism, and all-cause mortality. PATIENTS AND METHODS: Materials and Methods: We conducted a multicenter retrospective cohort study using the TriNetX database, identifying LVAD patients receiving either warfarin or apixaban. Two cohorts were established based on anticoagulation regimen, and propensity score matching was employed to minimize baseline differences. RESULTS: Results: After matching, 3,129 patients were included in each group. HRAEs occurred less frequently in the apixaban cohort (19.7%) than in the warfarin cohort (28.4%) (OR: 0.618; 95% CI: 0.513-0.744; P < 0.001). Apixaban was also associated with significantly fewer LVAD thrombosis events (OR: 0.088), strokes (OR: 0.721), and major bleeding events (OR: 0.528). Rates of non-CNS thromboembolism and all-cause mortality were similar between groups. CONCLUSION: Conclusions: Although warfarin remains the standard anticoagulant for LVAD recipients, apixaban demonstrated lower rates of major adverse events in this large retrospective analysis. Further prospective and randomized studies are warranted to confirm these findings and inform future clinical practice.